Iterum Therapeutics Files 8-K
Ticker: ITRM · Form: 8-K · Filed: Jul 22, 2024 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Jul 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
Iterum Therapeutics filed a routine 8-K on 7/22/24, mostly exhibits. Check full filing for details.
AI Summary
On July 22, 2024, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a significant event. No specific financial figures or new business developments were detailed in the provided excerpt.
Why It Matters
This filing indicates a routine update to the company's public disclosures, likely containing financial statements and exhibits. Investors should review the full filing for any material information.
Risk Assessment
Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, with no immediate indication of significant new risks or events.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- July 22, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 22, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 22, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at Fitzwilliam Court 1st Floor Leeson Close, Dublin 2, Ireland.
What is the Registrant's telephone number?
The Registrant's telephone number is +353 1 6694820.
What is the Standard Industrial Classification code for Iterum Therapeutics plc?
The Standard Industrial Classification code for Iterum Therapeutics plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-07-22 08:30:09
Key Financial Figures
- $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
Filing Documents
- itrm-20240722.htm (8-K) — 38KB
- itrm-ex99_1.htm (EX-99.1) — 25KB
- 0000950170-24-085057.txt ( ) — 185KB
- itrm-20240722.xsd (EX-101.SCH) — 26KB
- itrm-20240722_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On July 22, 2024, Iterum Therapeutics plc issued a press release announcing that it had commenced its previously disclosed subscription rights offering. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Iterum Therapeutics plc dated July 22, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: July 22, 2024 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer